Introduction
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are the most effective medications for reducing elevated concentrations of low-density lipoprotein (LDL) cholesterol, but statins can cause a variety of skeletal muscle problems including mylagia, creatine kinase (CK) elevation and rhabdomyolysis.
Statin-induced rhabdomyolysis is rare, occurring in only ∼0.1% of patients taking statin medication. However, the occurrence of myopathy has been estimated to range from 1 to 10%. 1 Although these reactions represent a relatively low risk of complications, many patients use statin medication, which may increase the proportion of myopathic complications. 2 Risk/benefit analysis of statin therapy is further complicated by the finding that exercise increases the risk of statin-induced myopathy. The prevalence of muscular symptoms is as high as 25% among statin users who exercise [2] [3] [4] and may exceed 75% in statin-treated athletes 3 . However, little is known about the mechanisms by which statins induce skeletal muscle injury. 5 Monocarboxylate transporter 4 (MCT4)
is a pH-dependent lactate transporter 6 and is expressed in skeletal muscle, especially in fast-twitch glycolytic fibers. 7 Westwood et al. reported that type I and IIB fibers represent metabolic extremes of a continuum of metabolic properties through the fiber types with type I fibers being most oxidative in metabolism and type IIB fibers being 4 most glycolytic and that simvastatin, one of the statins, impaired type IIB fibers more than type I fibers. 8 AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase, and skeletal muscle AMPK is activated by exercise. 9 Protein kinase C (PKC) plays important roles in intracellular signaling involved in many cellular responses.
10
Some PKC isoforms have a role in exercise-mediated glucose transport. 11 We previously reported that AMPK activation induced expression of MCT4 12 and that MCT4 expression was mediated through PKCδ in an RD cell line as a model of in vitro skeletal muscle. 13 Although we previously reported that α-cyano-4-hydroxycinnamate (CHC), an MCT4 inhibitor, increased the inhibition of growth of RD cells induced by cerivastatin, one of the statins, 14 it is unclear whether statin-induced RD cell cytotoxicity is associated with MCT4 expression. The aim of this study was to determine the relationship between statin-induced cytotoxicity and MCT4 expression in RD cells.
Materials and methods

Materials
Statins were obtained from Tokyo Chemical Industry (Tokyo, Japan). All other reagents were of the highest grade available and used without further purification. 
Cell culture
RD cells, a prototypic embryonal rhabdomyosarcoma cell line, are tumor cells of skeletal muscle origin that affect children and young adults and express a number of muscle-specific proteins, 15 and these cells have been used as a model for studying the myotoxic effects of statins. 16 , 17 RD cells were maintained in plastic culture flasks (Corning Incorporated Corning) as described previously. 18 
MTT assay
The 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide (MTT) assay was performed as described previously. 19 MTT is normally reduced by dehydrogenases of viable cells and transformed to formazan. Living, but not dead, cells are detected by this assay, and the signal generated is dependent on the degree of activation of cells. For the MTT assay, RD cells were transfected with Negative control or MCT4 siRNA and seeded on 96-well plastic plates. Following cell attachment (24 h), various concentrations of statins were added for the times indicated. Before the end of treatment, 10 µL of PBS-containing MTT solution (0.5%) was added, and the cells were incubated for a further 1 h. The MTT medium was then replaced with dimethyl sulfoxide, and 6 absorbance was read at 590 nm. Absorbance measured in MTT assays was expressed as percent of the control (defined as 100%).
Quantitative real-time PCR
Quantitative real-time PCR was performed using an Mx3000TM Real-time PCR System (STRATAGENE, Tokyo, Japan) with a KAPA SYBR Fast qPCR kit (KAPA Biosystems, Boston, MA) as per the manufacturer's protocol. PCR was performed using human MCT4-specific primers through 40 cycles of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min or using human 18S-specific primers. The primers specific to human MCT4 and 18S were designed on the basis of sequences in the GenBank™ database (accession no.: NM_004207, NM_001530 and NR_003286, respectively). The sequences of the specific primers were as follows: the sense sequence was 5′-ATT GGC CTG GTG CTG CTG ATG-3′and the antisense sequence was 5′-CGA GTC TGC AGG AGG CTT GTG-3′ for human MCT4, and the sense sequence was 5′
-CGG CTA CCA CAT CCA AGG AA-3′ and the antisense sequence was 5′-GCT GGA ATT ACC GCG GCT-3′ for human 18S. The PCR products were normalized to amplified 18S, which was the internal reference . 
Western blot analysis
Western blot analysis was performed as described previously. 12 Total protein extracts were prepared from RD cells. The cells were scraped and centrifuged at 1,500 × g for 1 min at 4 °C. The pellet was suspended in 1 mL of PBS and centrifuged at 1,500 × g for 
Caspase assay
The caspase assay was performed as described previously. 21 Cells were lysed with a cell culture lysis reagent (Promega, Madison, WI). Protein concentration of the cell lysate was adjusted to 10 µg/mL, and the cell lysate was subjected to caspase-3/7 colorimetric protease assays for measuring Ac-DEVD-pNa and Ac-LEHD-pNa cleavage as described in the manufacturer's protocol (Promega, Madison, WI).
Data analysis
Student's t-test was used to determine the significance of differences between two group means. Statistical significance among means of more than two groups was evaluated using Dunnett's test or Tukey's test. Statistical significance was defined as p < 0.05. 
Results
Effects of atorvastatin on cell viability and expression of MCTs in RD cells
We previously reported that alteration of monocarboxylate transporter (MCT) 4 function was associated with MCT4 expression levels in RD cells 13 and that lipophilic statins, atorvastatin, simvastatin and fluvastatin, significantly reduced RD cell viability in a concentration-dependent manner. 17 We therefore used RD cells and atorvastatin, simvastatin and fluvastatin in this study. First, we examined the effect of atorvastatin on RD cell viability and alteration in MCT4 mRNA level. Atorvastatin reduced the number of viable cells in a concentration-dependent manner and up-regulated MCT4 mRNA level ( Fig. 1) . Moreover, mRNA level of MCT4 in RD cells was also up-regulated by simvastatin and fluvastatin (Supplemental Fig. 1 ). On the other hand, MCT1 was reported to be responsible for L-lactate uptake, and L-lactate efflux was shown to be mediated by MCT4 in RD cells 18 . We therefore also investigated the effect of atorvastatin on MCT1 mRNA level. Atorvastatin did not affect mRNA level of MCT1 (Supplemental Fig. 2 ). The results suggest that atorvastatin-induced cytotoxicity is associated with MCT4 mRNA level but not with MCT1 mRNA level. 3B ). We established MCT4 knockdown conditions using MCT4 siRNA in RD cells and selected the conditions in the following study.
Establishment of MCT4 knockdown conditions in RD cells
Suppression of statin-induced cytotoxicity by MCT4 knockdown 12
We examined the effects of MCT4 knockdown on reduction of RD cell viability by statins. As shown in Fig. 3A , atorvastatin significantly reduced negative control cell viability in a concentration-dependent manner. On the other hand, MCT4 siRNAs 1 and 2 had a relieving effect on atorvastatin-induced reduction of cell viability. We previously reported that statin caused caspase-9, -3/7 activation and mainly induced apoptosis via a mitochondrial stress-induced cascade in RD cells. On the other hand, MCT4 siRNA 2 prevented these statin-induced reductions of cell viability and caspase-3/7 activation as in the case of atorvastatin. These observations 13 indicate that suppression of MCT4 expression leads to prevention of statin-induced reduction of cell viability and apoptosis.
Discussion
In a large study in the USA, the incidences of statin-induced rhabdomyolysis leading to hospitalization were zero for pravastatin, approximately 0.5 per 10,000 person-years for simvastatin and atorvastatin, and 5.3 per 10,000 person-years for cerivastatin. 22 Moreover, we previously reported that atorvastatin, simvastatin and fluvastatin significantly reduced cell viability more than did pravastatin. 17 Therefore, we used reported that simvastatin-induced impairment of mitochondria and alteration of Ca 2+ homeostasis occurred in intact rat skeletal muscle fibers from the flexor digitorum 14 brevis muscle but not in intact ventricular rat cardiomyocytes and that the simvastatin-induced alteration of Ca 2+ homeostasis was abolished when MCT4 was inhibited, indicating that the mechanism operates specifically in skeletal muscles. 23 Moßhammer et al. reported that it is not clear whether MCT4-mediated transport of statins across membranes of myocytes plays a role in myopathy. 24 We found that statin-induced cytotoxicity was associated with intracellular accumulation of statins. The conditions were identical to those described in the legend to Fig. 3 . 
